Short Interest in UCB SA (OTCMKTS:UCBJY) Decreases By 73.3%

UCB SA (OTCMKTS:UCBJY) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 800 shares, a drop of 73.3% from the October 31st total of 3,000 shares. Based on an average daily volume of 58,500 shares, the days-to-cover ratio is currently 0.0 days.

UCB Stock Down 1.1 %

OTCMKTS UCBJY traded down $1.08 during trading hours on Wednesday, hitting $95.37. 6,813 shares of the company’s stock were exchanged, compared to its average volume of 21,580. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The business’s 50 day moving average is $93.54 and its 200-day moving average is $84.04. UCB has a 12-month low of $36.70 and a 12-month high of $99.40.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.